Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Bacterin International inks 5-year purchasing deal for OsteoSponge products

|Includes: Xtant Medical Holdings, Inc. (XTNT)

Bacterin International Holdings (AMEX:BONE), a developer of bone graft material and anti-microbial coatings for medical applications, announced Monday a five-year purchasing deal with health care supply chain management company Resource Optimization & Innovation (ROi).

Under the terms of the agreement, Bacterin will provide its OsteoSponge product line, including the OsteoSelect stem cell-made allografts, as well as the Elutia Coated Wound Drain, to ROi's nationwide network of hospitals and medical practices. No financial terms were disclosed.

Bacterin uses its proprietary methods that optimize the growth factors in human allografts to create the ideal stem cell scaffold, promoting bone and other tissue growth.  These products are used for enhancing fusion in spine surgery, relief of back pain with joint stabilization, promotion of bone growth in foot and ankle surgery as well as cranial healing following neurosurgery. The company's medical division also develops antimicrobial coatings that inhibit contamination. 

"The inclusion of our products in ROi’s network is indeed a validation of our technology, as ROi uniquely includes physicians, clinicians, hospital leaders and other purchasing decision-makers’ input on product portfolio selection," said founder and CEO of Bacterin, Guy Cook.

"As a consequence, a number of surgeons affiliated with several hospitals within the ROi network have supported our entrance into the network and have been eagerly awaiting final approval to begin using our product line."

Headquartered in Belgrade, Montana, Bacterin operates a 42,000 square foot FDA registered facility.